SCHEMBL6184670

SCHEMBL6184670

CC(C)n1nnc2ccc(C(=O)C(Br)c3ccc(F)cc3)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 4/20 0.50
HPGD P15428 1/20 0.50
HCAR2 Q8TDS4 1/20 0.50
MAPK14 Q16539 1/20 0.46
CLK1 P49759 3/20 0.42
MGAM O43451 1/20 0.39
AMY1A P0DUB6 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
CCNT1 O60563 9/20 0.38
CDK9 P50750 9/20 0.38
CDK1 P06493 2/20 0.38
CDK2 P24941 2/20 0.38
CDK6 Q00534 2/20 0.38
CDK4 P11802 1/20 0.38
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
FGFR1 P11362 1/20 0.37
MAPK9 P45984 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183836 0.78 HCAR3 (0.51) HCAR3HPGDHCAR2MAPK14CLK1
SCHEMBL6184550 0.77 HCAR3 (0.80) HCAR3HPGDHCAR2CCNT1CDK9
SCHEMBL12349866 0.76 HCAR3 (0.64) HCAR3HPGDHCAR2MAPK14CCNT1
SCHEMBL19848372 0.75 MAPK14 (0.58) HCAR3HPGDHCAR2MAPK14CLK1
SCHEMBL9525250 0.73 HCAR3 (0.68) HCAR3HPGDHCAR2MAPK14CLK1
SCHEMBL6054729 0.72 MAPK14 (0.47) MAPK14
SCHEMBL2534850 0.72 CES2 (0.48) HPGDGSK3B
SCHEMBL6186432 0.69 HCAR3 (0.56) HCAR3HPGDHCAR2
SCHEMBL17807748 0.69 HCAR3 (0.50) HCAR3HPGDHCAR2MAPK14CLK1
SCHEMBL9523826 0.69 HCAR3 (0.51) HCAR3HPGDHCAR2MAPK14CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 HCAR3 495/4885HPGD 1292/4885HCAR2 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.